Silence Therapeutics Gestion
Gestion contrôle des critères 2/4
Silence Therapeutics' CEO is Craig Tooman, appointed in Feb 2022, has a tenure of 2.75 years. total yearly compensation is £7.30M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $197.33K. The average tenure of the management team and the board of directors is 2.1 years and 4.8 years respectively.
Informations clés
Craig Tooman
Directeur général
UK£7.3m
Rémunération totale
| Pourcentage du salaire du PDG | 6.5% |
| Durée du mandat du directeur général | 2.8yrs |
| Propriété du PDG | 0.02% |
| Durée moyenne d'occupation des postes de direction | 2.1yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.8yrs |
Mises à jour récentes de la gestion
Recent updates
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
Oct 04
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 18Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
Jun 17Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
May 21Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12New finance chief for Silence Therapeutics
Jan 06Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£40m |
| Mar 31 2024 | n/a | n/a | -UK£35m |
| Dec 31 2023 | UK£7m | UK£473k | -UK£43m |
| Sep 30 2023 | n/a | n/a | -UK£43m |
| Jun 30 2023 | n/a | n/a | -UK£41m |
| Mar 31 2023 | n/a | n/a | -UK£43m |
| Dec 31 2022 | UK£6m | UK£461k | -UK£40m |
| Sep 30 2022 | n/a | n/a | -UK£36m |
| Jun 30 2022 | n/a | n/a | -UK£39m |
| Mar 31 2022 | n/a | n/a | -UK£39m |
| Dec 31 2021 | UK£2m | UK£334k | -UK£39m |
Rémunération vs marché: Craig's total compensation ($USD9.43M) is above average for companies of similar size in the US market ($USD3.24M).
Rémunération et revenus: Craig's compensation has increased whilst the company is unprofitable.
PDG
Craig Tooman (59 yo)
2.8yrs
Titularisation
UK£7,298,000
Compensation
Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 2.8yrs | UK£7.30m | 0.024% $ 197.3k | |
| Executive VP | 2.8yrs | UK£2.50m | 0.0011% $ 8.9k | |
| Executive VP and Chief Research & Development Officer | 1.6yrs | UK£1.82m | 0.0092% $ 76.5k | |
| Chief Scientific Officer | less than a year | pas de données | pas de données | |
| Head of IR & Corporate Communications | no data | pas de données | pas de données | |
| Chief Human Resources Officer | less than a year | pas de données | pas de données | |
| Senior VP and Chief Intellectual Property & Innovation Officer | 2.2yrs | pas de données | pas de données | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 4.3yrs | pas de données | pas de données | |
| Chief Technical Operations Officer | 2yrs | pas de données | pas de données | |
| Chief Medical Officer | no data | pas de données | pas de données |
2.1yrs
Durée moyenne de l'emploi
61yo
Âge moyen
Gestion expérimentée: SLN's management team is considered experienced (2.1 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 2.8yrs | UK£7.30m | 0.024% $ 197.3k | |
| Independent Non-Executive Director | 6.4yrs | UK£184.00k | 0.0054% $ 44.3k | |
| Chairman of Scientific Advisory Board | 4.8yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 3.8yrs | UK£178.00k | 0.0092% $ 76.5k | |
| Independent Chairman of the Board | 5.6yrs | UK£402.00k | 0.078% $ 647.8k | |
| Member of Scientific Advisory Board | 4.8yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 5.6yrs | UK£182.00k | 0.011% $ 88.4k | |
| Member of Scientific Advisory Board | 4.8yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 4.8yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 4.4yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 2.8yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 2.8yrs | pas de données | pas de données |
4.8yrs
Durée moyenne de l'emploi
62yo
Âge moyen
Conseil d'administration expérimenté: SLN's board of directors are considered experienced (4.8 years average tenure).